Benitec Biopharma (BNTC) Return on Sales (2019 - 2024)
Historic Return on Sales for Benitec Biopharma (BNTC) over the last 6 years, with Q1 2024 value amounting to 3073.71%.
- Benitec Biopharma's Return on Sales fell 29932000.0% to 3073.71% in Q1 2024 from the same period last year, while for Mar 2024 it was 3073.71%, marking a year-over-year decrease of 27898300.0%. This contributed to the annual value of 254.85% for FY2023, which is 98400.0% down from last year.
- Latest data reveals that Benitec Biopharma reported Return on Sales of 3073.71% as of Q1 2024, which was down 29932000.0% from 356.05% recorded in Q4 2023.
- Benitec Biopharma's Return on Sales' 5-year high stood at 82.2% during Q2 2020, with a 5-year trough of 3933.75% in Q3 2021.
- Over the past 5 years, Benitec Biopharma's median Return on Sales value was 272.07% (recorded in 2023), while the average stood at 1091.01%.
- In the last 5 years, Benitec Biopharma's Return on Sales tumbled by -38848200bps in 2021 and then skyrocketed by 37227100bps in 2022.
- Benitec Biopharma's Return on Sales (Quarter) stood at 3261.0% in 2020, then surged by 94bps to 193.84% in 2021, then crashed by -107bps to 401.36% in 2022, then increased by 11bps to 356.05% in 2023, then crashed by -763bps to 3073.71% in 2024.
- Its Return on Sales stands at 3073.71% for Q1 2024, versus 356.05% for Q4 2023 and 272.07% for Q3 2023.